Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales
1. LLY shares dropped 14% after disappointing trial results for orforglipron. 2. Orforglipron's 12.4% weight loss was below expectations compared to Novo Nordisk's product. 3. Despite poor trial results, LLY reported strong Q2 earnings and revenue growth. 4. Sales of Zepbound and Mounjaro surged, indicating robust demand in the weight-loss segment. 5. LLY remains optimistic, seeking regulatory approval for orforglipron by year-end.